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Aberrantly glycosylated serum IgA1 are closely associated with
pathologic phenotypes of IgA nephropathy
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Aberrantly glycosylated serum IgA1 are closely associated with
pathologic phenotypes of IgA nephropathy.
Background. IgA nephropathy (IgAN) is the most common
glomerulonephritis with various histologic and clinical pheno-
types. The mechanisms underlying the pathogenesis of IgAN
remained unclear. But now altered O-glycosylation of serum
IgA1 observed in these patients was considered to be a key
contributory factor. The aim of the current study is to investi-
gate whether aberrantly glycosylated IgA1 was associated with
pathologic phenotypes of IgAN.
Methods Sera from 107 patients with IgAN recently diag-
nosed were collected. Fifty patients were with mild mesangial
proliferative IgAN, the others were with focal proliferative and
sclerosing IgAN. Sera from 22 normal blood donors were used
as normal controls. Biotinylated lectins were used in enzyme-
linked immunosorbent assay (ELISA) to examine different
glycans on IgA1 molecules. The a2,6 sialic acid was detected by
elderberry bark lectin (SNA), the exposure of terminal galac-
tose (Gal) and N-acetylgalactosamine (GalNAc) were detected
by arachis hypogaea [peanut agglutinin (PNA)] and vilsa villosa
lectin (VVL), respectively. The serum IgA1 glycans levels cor-
rected by serum IgA1 concentrations were compared between
patients and controls.
Results. Reduced terminal a2,6 sialic acid (1.16 ± 0.21 vs.
0.98 ± 0.31) (P = 0.008) and galactosylation (0.30 ± 0.29 vs.
0.16 ± 0.19) (P = 0.029) increased exposure of (GalNAc) (0.00
vs. 0.03) (P = 0.024) were demonstrated in serum IgA1 from
patients with IgAN as compared with those in controls. More
important, the exposures of 2,6 sialic acid and Gal were signifi-
cantly decreased, especially in patients with focal proliferative
and sclerosing IgAN compared with that in patients with mild
mesangial proliferative IgAN (0.91 ± 0.34 vs. 1.05 ± 0.25) (P =
0.014) (0.108 ± 0.137 vs. 0.221 ± 0.219) (P = 0.018). However,
no significant difference was found between patients with mild
mesangial proliferative IgAN and normal controls (P > 0.05).
The exposure of GalNAc of serum IgA1 from patients with focal
proliferative and sclerosing IgAN was significantly higher than
that of controls (P = 0.017), but had no statistical difference
with that of patients with mild mesangial proliferative IgAN.
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Conclusion. The desialylation and degalactosylation of IgA1
in sera of patients with IgAN were closely associated with patho-
logic phenotypes.
IgA nephropathy (IgAN) is the most common
glomerulonephritis in the world. It is characterized by
the deposition of polymeric IgA1 subclass in kidney
mesangium [1]. But the mechanism of IgA1 deposition
is unclear and it was suggested that IgA1 molecule was
involved in the pathogenesis of IgAN [2–5]. Our previ-
ous study demonstrated that heat aggregated serum IgA1
from patients with IgAN had a higher binding capacity
and stronger biologic effects to in vitro cultured human
mesangial cells than that from healthy controls. It was
suggested that serum IgA1 from patients with IgAN was
different to healthy people [6, 7].
Different to IgG, IgM, and IgA2, human serum IgA1
is one of the most exceptional of the human serum im-
munoglobulins because it has five O-linked oligosaccha-
rides in its hinge portion, in addition to the two N-linked
carbohydrate chains in its structure [8]. The abnormal
O-glycosylation of IgA1 has been well studied in recent
years, and there is increasing evidence for its involvement
in the pathogenesis of IgAN [9–13].
In general, it was agreed that IgA1 molecules from pa-
tients with IgAN displayed altered glycans moieties, usu-
ally with a reduced content of galactose (Gal) and sialic
acid [14–16]. Altered glycosylation of serum IgA1 could
favor the self-aggregation and/or the increased binding
to circulating glycoproteins, including fibronectin or envi-
ronmental alimentary, bacterial, or viral lectins as a result
of carbohydrate interactions [17, 18]. Macromolecules
could also be formed by the reaction between degalac-
tosylated (deGal) IgA1 and specific IgG antibodies
directed against IgA1 hinge O-glycans [19]. These IgA
immune or nonimmune aggregates could escape the
clearance by hepatic receptors for asialoglycoproteins
[20]. Moreover, the targeting to mesangial area might be
favored by carbohydrate interactions between aberrantly
glycosylated IgA and mesangial matrix, leading to accu-
mulation and/or prolonged persistence of IgA deposits
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within the mesangium [11]. Therefore, it was speculated
that altered hinge-region O-glycosylation of IgA1 might
play a pivotal role in the pathogenesis of IgAN.
It is well known that the histologic phenotypes of IgAN
are highly variable. Light microscopy findings range
from mild mesangial proliferation to a more diffuse pat-
tern with focal segmental scarring and even to crescen-
tic glomerulonephritis. But the association of different
pathologic phenotypes of IgAN and aberrantly glycosy-
lated serum IgA1 was not reported. Therefore, in this
study, we attempted to determine the association between
the altered O-glycans of serum IgA1 molecules and the
pathologic phenotypes of IgAN.
METHODS
Patients and sera
A total of 107 patients with IgAN were enrolled in the
current study, 53 were male and 54 were female, with a
mean age of 32.2 ± 11.7 years. Of the 107 patients with
IgAN, 50 were with mild mesangial proliferative glomeru-
lonephritis in renal pathology which means the glomeruli
showed no more than a minimal increase in mesangial
cellularity, without segmental sclerosis or crescents and
were defined as Haas-I, a pathologic scheme of IgAN pro-
posed by Haas [21]. The proteinuria of these 50 patients
was 2.79 ± 5.18 g/day and the mean serum creatinine was
63.6 ± 32.5 lmol/L, the mean duration of known disease
at the time of biopsy was 15.4 ± 30.5 months. There were
57 with focal proliferative sclerosing glomerulonephritis
in renal pathology, 42 of them were defined as Haas-III,
which means that 50% or fewer of the glomeruli were hy-
percelluar, less than 40% of the glomeruli were globally
sclerotic. The other 15 were defined as Haas-V, which in-
dicated that 40% or more of the glomeruli were globally
sclerotic. The proteinuria of these 57 patients was 3.61 ±
5.42 g/day and the mean serum creatinine was 147.5 ±
136.1 lmol/L, the mean duration of known disease at the
time of biopsy was 19.7 ± 28.8 months. Sera from patients
were obtained at the time of renal biopsy and sera from
22 normal blood donors with comparable age and gender
distribution were collected as normal controls.
Detection of glycans of serum IgA1 by sandwich
enzyme-linked immunosorbent assay (ELISA)
The O-glycans in the hinge region of IgA1 were de-
tected by specific lectin binding ELISA as previous re-
ported [22]. Rabbit antihuman IgA (Dako, Glostrup,
Denmark) diluted to 5.5 lg/mL in 0.05 mol/L bicarbonate
buffer, pH 9.6, and were coated to the wells of one half of
a polystyrene microtiter plates (Costar, Cambridge, MA,
USA). The wells in the other half were coated with bi-
carbonate buffer alone to act as antigen-free wells. The
volumes of each well for this step and for subsequent steps
were 100 lL, all incubations were carried out at 37◦C for 1
hour and the plate were washed by 0.01 mol/L phosphate-
buffered saline (PBS) containing 0.1% Tween-20 (PBST)
three times. Then the plate was blocked with PBST con-
taining 1% bovine serum albumin (BSA) (PBST/BSA).
The test sera diluted 1:200 in PBST/BSA were added
in duplication to both antigen-coated and antigen-free
wells. Every plate contained blank control (PBST/BSA)
and a known normal serum was used as a positive con-
trol. After incubation and washing, the biotinylated sec-
ond antibodies or lectins in PBST/BSA were added,
including 1:20,000 diluted monoclonal antihuman IgA1
(clone A1-18) (Sigma Chemical Co., St. Louis, MO, USA)
to detect the IgA1 concentrations; 1:500 diluted elder-
berry bark lectin (Sambucus Nigra Agglutinin; SNA)
(Vector Laboratory, Burlingame, CA, USA) to detect
serum a2,6 sialic acid; 1:200 diluted arachis hypogaea
[peanut agglutinin (PNA)] (Sigma Chemical Co.) or
vilsa villosa lectin (VVL) (Vector Laboratory) to de-
tect Gal and N-acetylgalactosamine (GalNAc), respec-
tively. The wells were then incubated with 1:20,000 diluted
avidin-horseradish peroxidase (HRP) (Sigma Chemi-
cal Co.). The results were revealed with 0.1 mol/L cit-
rate phosphate buffer, pH 5.0, containing 0.04% O-
phenylenediamine (OPD) and 0.1% H2O2 (vol/vol), then
the reaction was stopped with 1 mol/L H2SO4. The ab-
sorbance at 490 nm (A) was recorded in an ELISA reader
Bio-Rad 550 (Bio-Rad, Tokyo, Japan).
The relative concentration of serum IgA1 and the level
of glycans were calculated as following: the A value of
the blank control was regarded as 0, the A value of the
known control was regarded as 100%, and the A value of
each sample was calculated by log-transformed data. The
relative lectin binding per unit IgA1 was calculated as the
A value of lectin over the A value of IgA1 concentration.
Statistics
For statistical analysis, statistical software SPSS version
11.0 (SPSS, Chicago, IL, USA) was employed. Quanti-
tative data were expressed as mean ± SD and median
with range (minimum and maximum). For comparison
between patients and controls, the Student t test, two-
way analysis of variance (ANOVA), and Mann-Whitney
U test were performed. Statistical significance was con-
sidered as P < 0.05.
RESULTS
Comparison of serum IgA1 glycosylation between
patients with IgAN and normal controls
The levels of a2,6 sialic acid and Gal of serum IgA1
were lower in patients with IgAN compared with that of
normal controls (0.98 ± 0.31 vs. 1.16 ± 0.21) (P = 0.008)
(0.16 ± 0.19 vs. 0.30 ± 0.29) (P = 0.029), respectively,
and the exposure of GalNAc of serum IgA1 was higher
Xu and Zhao: Abberantly glycosylated serum IgA1 169
Table 1. Comparison of levels (arbitrary units) of a2,6 sialic acid,
galactose (Gal), and N-acetylgalactosamine (GalNAc) between
patients with IgA nephropathy (IgAN) and controls
Normal Patients
controls with IgAN
(N = 22) (N = 107) P value
Sialic acid 1.16 ± 0.21 0.98 ± 0.31 0.008
Gal 0.30 ± 0.29 0.16 ± 0.19 0.029
0.250 (0, 1.07) 0.107 (0, 0.844)
GalNAc 0.00 (0, 0.33) 0.03 (0, 0.29) 0.024
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Fig. 1. The exposure of a2,6 sialic acid of serum IgA1 molecules mea-
sured by SNA between different pathologic phenotypes and normal
controls. The serum IgA1 in normal controls (NC) and patients with
mild mesangial proliferative IgA nephropathy (IgAN) (MIgAN) ex-
posed more a2,6 sialic acid than in patients with focal proliferative
sclerosing IgAN (FIgAN). SNA, sambucus nigra agglutinin.
in patients with IgAN than that in controls (0.03 vs. 0.00)
(P = 0.024) (Table 1).
Comparison of serum IgA1 glycosylation between
patients with different pathologic phenotypes and
normal controls
When patients were further stratified, the levels of a2,6
sialic acid and Gal of serum IgA1 were much lower in pa-
tients with focal proliferative sclerosing IgAN compared
with that in patients with mild mesangial proliferative
IgAN (0.91 ± 0.34 vs.1.05 ± 0.25) (P = 0.014) (0.108 ±
0.137 vs. 0.221 ± 0.219) (P = 0.018), respectively, and that
in normal controls (0.91 ± 0.34 vs. 1.16 ± 0.21) (P = 0.001)
(0.108 ± 0.137 vs. 0.297 ± 0.292) (P = 0.001), respectively
(Figs. 1 and 2). The exposure of GalNAc of serum IgA1
in patients with focal proliferative sclerosing IgAN was
higher than that in normal controls (0.02 vs. 0.00) (P =
0.017) but was comparable to that in patients with mild
mesangial proliferative IgAN (P = 0.692) (Fig. 3). When
the levels of a2,6 sialic acid, Gal, and GalNAc were com-
pared between patients with mild mesangial prolifera-
tive IgAN and normal controls, no significant difference
could be found (1.16 ± 0.21 vs. 1.05 ± 0.25) (P = 0.134)
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Fig. 2. The exposure of galactose (Gal) of serum IgA1 molecules mea-
sured by peanut agglutinin (PNA) between different pathologic phe-
notypes and normal controls. The serum IgA1 in normal controls (NC)
and patients with mild mesangial proliferative IgA nephropathy (IgAN)
(MIgAN) exposed more Gal than in patients with focal proliferative
sclerosing IgAN (FIgAN).
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Fig. 3. The exposure of N-acetylgalactosamine (GalNAc) of serum
IgA1 molecules measured by vilsa villosa lectin (VVL) between dif-
ferent pathologic phenotypes and normal controls. The serum IgA1 in
patients with focal proliferative sclerosing IgA nephropathy (IgAN)
(FIgAN) exposed more GalNAc than in normal controls. MIgAN is
mild IgAN.
(0.297 ± 0.292 vs. 0.221 ± 0.219) (P = 0.147) (0.03 vs. 0.00)
(P = 0.071), respectively (Table 2).
DISCUSSION
The IgA1 hinge region is a very unique mucin-like
O-linked glycopeptide. The core peptide has a proline-,
serine-, and threonine-rich amino acid sequence in which
the five serines are able to carry O-linked oligosaccha-
rides consisting of sialic acid, Gal, and GalNAc with
microheterogeneity [23, 24]. Altered O-glycosylation of
IgA1 in IgAN is a physicochemical abnormality of the
IgA1 molecule that may contribute to pathogenic mech-
anisms in a number of ways. But the precise structural
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Table 2. Comparison of the levels (arbitrary units) of a2,6 sialic acid, galactose (Gal), and N-acetylgalactosamine (GalNAc) in patients with
different pathologic phenotypes
Normal Normal control vs. Mild mesangail
Normal Mild mesangial Focal proliferative control vs. mild focal proliferative IgA nephropathy vs.
controls IgA nephropathy sclerosing IgA mesangial IgA sclerosing focal proliferative
(N = 22) (N = 50) nephropathy (N = 57) nephropathy IgA nephropathy sclerosing IgA nephropathy
Sialic acid 1.16 ± 0.21 1.05 ± 0.25 0.91 ± 0.34 P = 0.134 P = 0.001 P = 0.014
Gal 0.297 ± 0.292 0.221 ± 0.219 0.108 ± 0.137 P = 0.147 P = 0.001 P = 0.018
0.250 (0, 1.07) 0.150 (0, 0.84) 0.058 (0, 0.616)
GalNAc 0.000 (0, 0.33) 0.031 (0, 0.22) 0.018 (0, 0.29) P = 0.071 P = 0.017 P = 0.692
nature of defect remains to be fully characterized. Al-
though the lectin-binding assays only afforded the indi-
rect evidence of the glycans and could not give the precise
structure of the sugar residues, it was suggested that the
lectin-binding assay was a simple and effective method to
detect different glycans of IgA1 molecules and it had a
good correlation with fluorophore-assisted carbohydrate
electrophoresis (FACE) and mass spectrometry in the
detection of Gal and GalNAc [3, 22].
In the present study, a modified ELISA using anti-
human IgA1 as the coating reagent and biotinylated-
conjugated lectins as probes were performed to analyze
the interaction of lectins with serum IgA1 of normal sub-
jects and patients with IgAN. The results showed that the
serum IgA1 from patients with IgAN had decreased ex-
posure of a2,6 sialic acid and Gal but increased exposure
of GalNAc, especially the IgA1 from patients with fo-
cal proliferative sclerosing IgAN (Haas-III or-V). How-
ever, for patients with mild mesangial proliferative IgAN
(Haas-I), they were similar to that in healthy controls. To
our knowledge, this is the first study demonstrating that
a2, 6 sialic acid deficiency and Gal deficiency of serum
IgA1 have close association with renal pathologic phe-
notypes of IgAN. It was well known that the advanced
renal pathology usually indicated a worse prognosis in
patients with IgAN. We speculated that the deficiency
of sialylation and galactosylation of serum IgA1 might
be associated with the prognosis of patients with IgAN.
This is a strong support to the speculation of Coppo and
Amore [25] that defects in IgA1 glycosylation might in-
fluence the presentation and natural history of patients
with IgAN. However, no correlation between clinical pa-
rameter such as the duration of known disease at the time
of biopsy, the serum creatinine, albumin, or the amount
of the proteinuria and the lectin binding had been found.
Lectins are proteins derived from various plants and an-
imals which display binding affinity for certain specific
carbohydrate ligands. However, correlation between
lectin-binding assays designed to identify alteration in
sialic acid and precise sialic acid contents still need to
be confirmed by sophisticated measurements.
Increasing evidences suggested that the serum IgA1
from patient with IgAN had deficiency of a2,6 sialic acid
and Gal residues and increased exposure of GalNAc by
different methods, such as lectin-binding assay, gas-phase
hydrazinolysis analysis, mass spectrometry, or FACE [3, 4,
11, 15]. Iwase et al [17] studied the heat-aggregated serum
IgA1 and heat-stable serum IgA1 and indicated that the
heat-stable IgA1 contained a much higher amount of the
sialylated Galb1, 3 GalNAc. They also detected abun-
dant asialo-Galb1, 3 GalNAc (TF antigen) in the IgA1
molecule from patients with IgAN and indicated that the
incompleteness of the sugar chain of IgA1 corresponded
to a decrease in the sialic acid content of hinge O-glycan
chain [26]. Milan et al [12, 13] found that serum IgA1
from patients with IgAN was deficient in Gal and that
the serum IgA1 molecules with Gal deficiency could be
bound with IgG to form high molar mass complexes, and
they also demonstrated that circulating immune com-
plexes in IgAN consisted of IgA1 with Gal deficiency in
hinge region and antiglycan antibodies. When enzymat-
ically deglycosylated IgA1 were injected into the renal
artery of rats, distinct amounts of desialylated IgA1 and
degalactosylated IgA1 could be observed in rat glomeruli.
However, untreated IgA1 molecules (native IgA1) could
not be found with obvious accumulation. These results
suggested that underglycosylation of IgA1 might play an
important role in the glomerular accumulation of IgA1
[9]. More important, Hiki et al [4] and Allen et al [5] had
demonstrated that the sialic acid and Gal in the IgA1
eluted from renal biopsy tissue of patients with IgAN
were significantly decreased and the deposited IgA1 had
the same abnormal physicochemical features as serum
IgA in IgAN.
Aberrantly glycosylated IgA could circulate in a
monomeric form, and could participate in the formation
of autoaggregates or true immune complexes. The sialic
acid at the hinge region are large and bulky compared
with the protein backbone of IgA1, and they carry neg-
atively charge, any change in the carbohydrate moieties
affects the tertiary structure as well as the electrostatic
charges [27]. It was thought that electrostatic repulsion
and steric hindrance due to the sialic acid residues might
play an important role on stability of IgA1 molecule as
Kokubo et al [11] described. The IgA1 molecular could
bind to hepatic asioglycoprotein receptors (ASGPR) by
Gal, the deficiency of Gal might escape clearance by liver
and make the serum IgA1 increased; furthermore, the
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exposure of GalNAc could act as an neoautoantigen that
might be recognized by naturally occurring antibodies
(IgG or IgA1 specific for GalNAc) or in IgA1-IgA1 inter-
actions [13, 28]. Macromolecular IgA1 complexes formed
by either of these mechanisms might be particularly prone
to mesangial trapping [13]. It was reported by Kokubo
et al [29] that the IgA1-IgA1 interaction could be me-
diated by the core structure, including the peptide and
the sugars, except for sialic acid, and the removal of sialic
acid and Gal residues from IgA1 molecules could result
in a significant increase in the adhesion activities to the
mesangial matrix glycoproteins and a significant increase
in complement-binding properties [30, 31].
Our previous work clearly demonstrated that aggre-
gated IgA1 from patients with IgAN had a higher bind-
ing capacity to human mesangial cells and could induce
mesangial cells proliferation and enhance the produc-
tion of profibrosing cytokine transforming growth factor-
b (TGF-b) and extracelluar matrix fibrinogen [6, 7].
The activation of mesangial cells by Gal-deficient IgA1-
containing circulating immune complexes was considered
to be the initiating event in the pathogenesis of IgAN.
In vitro, mesangial cell activation was observed in many
instances upon the binding of IgA or IgA1-immune com-
plexes (depending on the amount and form of IgA) [32,
33]. In vivo, it was found that urinary interleukin (IL)-6,
the tubular and interstitial expression of intercellular ad-
hesion molecular type 1, and the intrarenal expression of
proinflammatory cytokines and chemokines could corre-
late with renal injury and might have a prognostic value
[34, 35].
The renal pathologic phenotypes of IgAN were highly
variable, and not always correlated with clinical param-
eters. Based on our finding, we speculated that the aber-
rant glycosylations of IgA1 might affect the glomerular
response to IgA1 deposition as well as to the mechanism
of deposition. However, this hypothesis needs further in-
vestigation.
CONCLUSION
Undersialylation and undergalactosylation of serum
IgA1 from patients with IgAN might be associated with
the pathologic phenotypes.
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